{
    "nanopub": {
        "schema_uri": "https://raw.githubusercontent.com/belbio/schemas/master/schemas/nanopub_bel-1.0.0.yaml",
        "type": {
            "name": "BEL",
            "version": "2.0.0"
        },
        "annotations": [
            {
                "type": "Disease",
                "label": "Carcinoma, Renal Cell"
            },
            {
                "type": "Anatomy",
                "label": "cardiovascular system endothelium"
            },
            {
                "type": "TextLocation",
                "label": "Review"
            },
            {
                "type": "Cell",
                "label": "fibroblast"
            },
            {
                "type": "Anatomy",
                "label": "Muscle, Smooth, Vascular"
            },
            {
                "type": "CellLine",
                "label": "U-937 cell"
            },
            {
                "type": "CellStructure",
                "label": "Cell Membrane"
            },
            {
                "type": "Species",
                "label": "9606"
            }
        ],
        "citation": {
            "authors": [
                "Barry, Robert E",
                "Krek, Wilhelm"
            ],
            "database": {
                "name": "PubMed",
                "id": "15350900"
            },
            "reference": "Trends in molecular medicine",
            "title": "The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.",
            "source_name": "Trends in molecular medicine",
            "date_published": "2004-09-01"
        },
        "assertions": [
            {
                "subject": "proteinAbundance(HGNC:VHL)",
                "relation": "directlyIncreases",
                "object": "degradation(proteinAbundance(HGNC:PRKCI))"
            }
        ],
        "evidence": "pVHL has been shown to bind directly to various aPKC isoforms and to target aPKCl for ubiquitin-mediated degradation [39,40].",
        "metadata": {
            "statement_group": "Group 3"
        }
    }
}
